1. All Products
  2. DVAC - Vaccines
  3. VACCINE MENINGITIS CJ A+C+W135+Y,monod.+dil.0.5ml (Nimenrix)
Public Pricelist

VACCINE MENINGITIS CJ A+C+W135+Y,monod.+dil.0.5ml (Nimenrix)

https://medicalguidelines.msf.org/en/node/272
https://unicat.msf.org/cat/product/69823
NST DVACVMEN3VWCJ

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
19.3 - Vaccines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J07AH08
Anatomical Therapeutic Chemical Classification according to WHOCC
PF
The order of this product needs to be justified and is only acceptable under certain conditions.
0208
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

VACCINE MENINGITIS CONJ. A+C+W135+Y

Menveo® vaccine is the first choice. However, it is not always available at supply centre level. In this case, Menactra® or Nimenrix® (non-standard) vaccines can be an alternative. Contact your section pharmacist for more information.

Therapeutic Action

Meningococcal Group A, C, W-135 and Y inactivated conjugate vaccine

Indications

Active immunisation against meningitis due to Neisseria meningitidis groups A, C, W-135 and Y in infants, children, adolescents and adults at risk of invasive disease (e.g. persons with functional or surgical asplenia)

.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Must be given as IM injection.

Depending on the vaccine used, vaccination age for infants may vary:

  • Menveo®: from 2 months of age
  • Menactra®: from 9 months of age
  • Nimenrix®: from 6 weeks of age

Depending on the vaccine used, composition and dilution may vary:

  • Menveo®: lyophilised active component to be reconstituted with the diliuent before use
  • Menactra®: liquid vaccine, ready-to-use
  • Nimenrix®: lyophilised active component to be reconstituted with the diluent before use

Precautions for Use

As with all injectable vaccines and/or immunoglobulins, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the product.

Storage

  • Keep refrigerated between 2°C and 8°C - Protect from sunlight
  • Do not freeze.
  • The vaccine vial monitor (VVM) is mandatory on each vaccine in multi-dose presentation.

(Cf Introduction: Thermosensitive products)